NBRV News and Press, Nabriva Therapeutics plc From 06/02/21

DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Dr. Ma...

Gainers: Asensus Surgical ASXC +37%, Nabriva Therapeutics (NBRV) +29%, Kintara Therapeutics KTRA +26%, Owens & Minor (OMI) +21%, Protagenic Therapeutics (PTIX) +10%.Losers: Larimar Therapeutics LRMR -37%, Travere Therapeutics TVTX ...

Nabriva Therapeutics (NBRV) +51% as its Nabriva antibiotic meets primary endpoint.Pieris Pharmaceuticals (PIRS) +20%.Protagenic Therapeutics (PTIX) +11%.Zscaler (ZS) +11% on Q3 results.Urban Outfitters (URBN) +11% on Q1 results.Selecta Biosciences (SELB) +10% as board dire...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! Get ready for another busy day of trading as we hit the midpoint of the week. Join us as we kick off the day with a look at the biggest pre-market stock movers for Wednesday. Source: Shutterstoc...

Nabriva Therapeutics (NBRV) and Sinovant Sciences' antibiotic lefamulin was non-inferior to moxifloxacin in a phase 3 study, according to top-line results.The randomized, double-blind study in 125 patients with community acquired bacterial pneumonia compared the efficacy and safety of IV/oral...

Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients meeting the efficacy endpoint of Investigator Assessment of Clinical Response (IACR) at Test of Cure (TOC), compared to 71.4% of patients treated with moxifloxacin Lefamulin was generally ...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroede...

Nabriva Therapeutics plc (NBRV) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Dan Dolan - Chief Financial Officer Ted Schroeder - Chief Executive Officer Conference Call Participants Ed Arce - H.C. Wainwright Presentation Operator Thank you for all for standing ...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2021 Q1 earnings call. For further details see: Nabriva Therapeutics plc 2021 Q1 - Results - Earnings Call Presentation

Nabriva Therapeutics (NBRV): Q1 GAAP EPS of -$0.53 beats by $0.14.Revenue of $2.52M (+219.0% Y/Y) beats by $0.27M.Press Release For further details see: Nabriva Therapeutics EPS beats by $0.14, beats on revenue